Table 1 The clinical and laboratory data of MPO-ANCA patients and healthy controls
Parameters | Active patients (n = 34) | Remission patients (n = 8) | Healthy controls (n = 10) | P value |
|---|---|---|---|---|
Male/female | 15/19 | 4/4 | 6/4 | 0.672 |
Age (years) | 63 (57.75, 68.25) | 64.5 (61, 67.50) | 59.5 (37.25, 69.25) | 0.577 |
BVAS | 15 (13, 16.25) | 0 (0, 0) | < 0.001 | |
Scr (μmol/l) | 182.5 (107.25, 286.75) | 63 (48.25, 83.5) | < 0.001 | |
HB (g/l) | 97.82 ± 21.53 | 115.8 ± 17.24 | 0.035 | |
WBC (109/l) | 8.55 ± 3.46 | 8.97 ± 3.49 | 0.757 | |
PLT (109/l) | 275.18 ± 100.36 | 307.88 ± 153.25 | 0.460 | |
ANCA levels (IU/ml) | 154.89 ± 84.84 | 35.99 ± 21.69 | < 0.001 | |
CRP (mg/dl) | 1.01 (0.27,6.91) | 0.49 (0.39, 0.89) | 0.364 | |
C3 (mg/dl) | 88.28 ± 17.99 | 96.98 ± 19.67 | 0.235 | |
C4 (mg/dl) | 25.85 ± 8.90 | 22.81 ± 8.27 | 0.386 | |
ESR (mm/1 h) | 55 (36, 65.5) | 24.5 (14, 65.50) | 0.015 | |
SF (ng/ml) | 333.46 ± 265.27 | 210.8 ± 160.8 | 0.210 | |
D-Dimer (ng/ml) | 1856 (652, 3935) | 910 (582, 3938) | 0.428 | |
RF (IU/ml) | 20 (20, 48.1) | 30.95 (20, 49.88) | 0.588 | |
ALB (g/l) | 31.88 ± 5.99 | 34.25 ± 5.50 | 0.314 | |
Proteinuria (g/24 h) | 1.55 (0.55, 1,99) | |||
Hematuria(number/μl) | 224.5 (31.58, 712.08) | |||
NGAL (ng/ml) | 32.68 (13.92, 74.26) | |||
Disease duration (months) | 3 (1.43, 6.13) | |||
Renal | 100% | |||
Lung | 41% | |||
ENT | 6% | |||
Joint | 14% | |||
Gastrointestinal | 9% | |||
Skin | 12% |